MedPath

INmune Bio

INmune Bio logo
🇺🇸United States
Ownership
Public
Established
2015-01-01
Employees
17
Market Cap
-
Website
http://www.inmunebio.com
Introduction

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Clinical Trials

7

Active:2
Completed:1

Trial Phases

2 Phases

Phase 1:3
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (57.1%)
Phase 1
3 (42.9%)

Study of INKmune in Patients With mCRPC (CaRe Prostate)

Phase 1
Recruiting
Conditions
Metastatic Castration-resistant Prostate Cancer
Cancer
mCRPC
Interventions
First Posted Date
2023-09-28
Last Posted Date
2025-05-13
Lead Sponsor
Inmune Bio, Inc.
Target Recruit Count
30
Registration Number
NCT06056791
Locations
🇺🇸

VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

and more 4 locations

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

Phase 1
Terminated
Conditions
Cancer
MDS-EB
Acute Myeloid Leukemia
Myelodysplastic Syndromes
AML
First Posted Date
2023-07-06
Last Posted Date
2024-07-18
Lead Sponsor
Inmune Bio, Inc.
Target Recruit Count
2
Registration Number
NCT05933070
Locations
🇬🇷

Attikon University General Hospital, Athens, Attiki, Greece

🇬🇧

University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom

🇬🇧

Sheffield Teaching Hospitals NHS FT - Royal Hallamshire Hospital, Sheffield, United Kingdom

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Phase 2
Active, not recruiting
Conditions
Central Nervous System Diseases
Tauopathies
Mental Disorders
Alzheimer Disease
Brain Diseases
Dementia
Neurodegenerative Diseases
Neurocognitive Disorders
Nervous System Diseases
Interventions
First Posted Date
2022-08-31
Last Posted Date
2024-08-09
Lead Sponsor
Inmune Bio, Inc.
Target Recruit Count
11
Registration Number
NCT05522387
Locations
🇦🇺

KaRa MINDS, Macquarie Park, New South Wales, Australia

🇦🇺

Neuro Trials Victoria Pty Ltd T/A NeuroCentrix, Carlton, Victoria, Australia

🇦🇺

Austin Health, Ivanhoe, Victoria, Australia

and more 1 locations

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Phase 2
Withdrawn
Conditions
Dementia
Mild Cognitive Impairment (MCI)
Alzheimer Disease
Brain Diseases
Nervous System Diseases
Central Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Mental Disorders
Interventions
Drug: Placebo
First Posted Date
2022-04-11
Last Posted Date
2023-09-28
Lead Sponsor
Inmune Bio, Inc.
Registration Number
NCT05321498

A Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation

Phase 2
Active, not recruiting
Conditions
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Mild Cognitive Impairment
Interventions
Drug: Placebo
First Posted Date
2022-04-08
Last Posted Date
2025-03-07
Lead Sponsor
Inmune Bio, Inc.
Target Recruit Count
201
Registration Number
NCT05318976
Locations
🇬🇧

INmune Bio Investigational Site, Winchester, United Kingdom

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.